ECONSALUT

  Modernización de los servicios sociales en España: Diseño de un nuevo marco estatal Modernising Social Services in Spain Designing a New N...

 Big Med. Megaproviders and the High Cost of Health Care in America Dranove and Burns trace Big Med’s emergence in the 1990s, followed by it...

 LA EVALUACIÓN DE LA EFICIENCIA DE LAS TECNOLOGÍAS SANITARIAS EN ESPAÑA: ORIGEN, EVOLUCIÓN Y ESTADO ACTUAL Key message: La información que g...

 Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets The 2018 OECD report Pharmaceutical Inno...

 Pricing for Medicine Innovation: A Regulatory Approach to Support Drug Development and Patient Access The message: We introduce a regulator...

 Medical Professionalism In An  Organizational Age: Challenges And Opportunities This article aims to start a dialogue on how these changes ...

 CRISPR: Genome Editing and Engineering And Related Issues

 The Ethics of Pandemics. An Introduction Table of Contents 1. Introduction: Why Ethics of Pandemics? 2. The General Principle of Pandemic R...

Nudging How “nudges” by government can empower citizens without manipulating their preferences or exploiting their biases. We're all fam...

 The Truth About the Drug Companies. HOW THEY DECEIVE US AND WHAT TO DO ABOUT IT From the former editor-in-chief of the New England Journal ...

Science needs to move beyond luck if it is to design better drugs for the brain The Economist: Between 2011 and 2020 the likelihood of a dru...

The next generation of rare disease drug policy: ensuring both innovation and affordability The study finds that while 5% of drugs with an o...

  Introduction to Market Access for Pharmaceuticals Contents: Chapter 1: Health as a Good Chapter 2: Decision-Making in Public Health Chapte...

 Build a think tank. A guide for policy entrepreneurs Using this guide 8 The reasons for creating this companion guide 8 Using this companio...